Such studies offercritical insights into the field of targeting MYC for cancer.19 Following up on experiences gained from ourwork with small-molecule MYC inhibitors20 and based on accomplishments with hybrid structure bioactive moleculedevelopment,21 we have expanded our objectivesto discover MYC-specific degraders. The gene discussed is MYC; the disease is cancer.